Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion type Assertion NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_head.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion description "[Utilizing a large panel of human GCT tissue samples, we found that AMH type I receptors (ALK2, ALK3 and ALK6) and type II receptor (AMHRII), as well as their downstream effectors Smad1/5, are expressed and active in GCTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_provenance.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion evidence source_evidence_literature NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_provenance.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion SIO_000772 21808236 NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_provenance.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion wasDerivedFrom befree-20150227 NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_provenance.
- NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_assertion wasGeneratedBy ECO_0000203 NP222212.RAvt1lmgevfedQ5U-v-KgczhcVt5wq4rNBBpF_efD0TCU130_provenance.